钙泊三醇倍他米松软膏治疗慢性湿疹临床疗效观察  

Clinical observation of calcipotriol betamethasone ointment in the treatment of chronic eczema

作　　者：王芳[1] 曹光玲[1] 戚世玲[1] 张小婷[1] 章星琪[1] 

机构地区：[1]中山大学附属第一医院皮肤科,广东广州510080

出　　处：《临床皮肤科杂志》2014年第3期179-181,共3页Journal of Clinical Dermatology

摘　　要：目的:探讨钙泊三醇倍他米松软膏外用治疗慢性湿疹的临床疗效与安全性。方法:入选的100例慢性湿疹患者随机分为两组,试验组予外用钙泊三醇倍他米松软膏,对照组外用卤米松软膏,均为每日1次使用。于首次用药后第2、4周观察临床疗效与安全性。结果:治疗4周后,试验组的有效率为91.67%,优于对照组的63.83%(P<0.05)。治疗2周及4周后,试验组湿疹严重度和面积指数(EASI)评分下降百分比均高于对照组(P值均<0.05)。治疗结束后,试验组未出现毛细血管扩张、色素改变及皮肤变薄等糖皮质激素不良反应。结论:钙泊三醇倍他米松软膏治疗慢性湿疹具有良好的疗效与安全性。Objective： To assess the clinical efficacy and safety of calcipotriol betamethasone ointment in patients with chronic eczema. Methods： One hundred patients with chronic eczema were randomly divided into two groups treated with either calcipotriol betamethasone ointment once daily or halometasone ointment once daily. The safety and efficacy of the two regimens were evaluated at week 2 and 4 after treatment. Results： After 4 weeks of treatment, the effective rate in calcipotriol betamethasone-treated group was higher than that in control group （91.67% vs. 68.83%, P〈0.05）. After 2 and 4 weeks of treatment, calcipotriol betamethasone-treated patients experienced a greater decrease in eczema area and severity index （EASI） as compared with halometasone-treated patients （P〈0.05）. Calcipotriol betamethasone treatment did not cause severe adverse reactions. Conclusions： Once daily calcipotriol betamethasone ointment is an effective and safe treatment for chronic eczema.

关 键 词：湿疹 慢性 钙泊三醇 倍他米松 

分 类 号：R758.23[医药卫生—皮肤病学与性病学]